RGEN

Repligen Corporation NASDAQ

Healthcare ·Medical - Instruments & Supplies ·US · repligen.com

$125.61

Mkt Cap $7.1B

52w Low $109.50 24.3% of range 52w High $175.77

50d MA $121.20 200d MA $138.02

P/E (TTM) 134.7x

EV/EBITDA 56.8x

P/B 3.1x

Debt/Equity 0.3x

ROE 2.3%

P/FCF 98.1x

RSI (14) —

ATR (14) —

Beta 1.19

50d MA $121.20

200d MA $138.02

Avg Volume 1.1M

About

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS p…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 24, 2026	BMO	0.44	0.49	+11.4%	135.40	-9.7%	-0.5%	-2.4%	-1.3%	-4.9%	-7.7%	—
Oct 28, 2025	BMO	0.42	0.46	+9.5%	161.10	+2.4%	-5.9%	-7.8%	-10.3%	-7.5%	-6.8%	—
Jul 29, 2025	BMO	0.40	0.37	-7.5%	119.65	+5.3%	+4.7%	+2.7%	-2.2%	-0.6%	-2.6%	—
Apr 29, 2025	BMO	0.35	0.39	+11.4%	143.63	-5.9%	-2.9%	-3.9%	-4.5%	-1.5%	-1.9%	—
Feb 20, 2025	BMO	0.41	0.44	+7.3%	150.73	+4.8%	+7.9%	+5.5%	+9.3%	+7.1%	+8.0%	—
Nov 12, 2024	BMO	0.34	0.43	+28.2%	139.51	+5.7%	+6.5%	+7.9%	+2.1%	-10.6%	-11.5%	—
Jul 30, 2024	BMO	0.33	0.33	+0.0%	138.00	+10.6%	+16.4%	+21.3%	+20.1%	+17.2%	+17.5%	—
May 1, 2024	BMO	0.29	0.28	-3.4%	164.20	-3.2%	-3.6%	+1.3%	+1.7%	+2.3%	+2.1%	—
Feb 21, 2024	BMO	0.34	0.33	-2.9%	199.73	-6.0%	-2.8%	-3.2%	-1.6%	-4.0%	-3.5%	—
Oct 31, 2023	BMO	0.14	0.23	+64.3%	114.17	+17.9%	+17.9%	+15.1%	+19.6%	+31.7%	+26.1%	—
Aug 2, 2023	BMO	0.49	0.53	+8.2%	167.12	-1.1%	+2.0%	+1.1%	+3.4%	+2.5%	+3.4%	—
May 2, 2023	BMO	0.59	0.64	+8.5%	153.54	+2.0%	+2.4%	+6.4%	+2.4%	+4.3%	+2.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 20	Canaccord Genuity	Maintains	Hold → Hold	—	$131.21	$130.82	-0.3%	+0.6%	+1.1%	-5.2%	-13.1%	-10.4%
Apr 14	Barclays	Maintains	Overweight → Overweight	—	$122.59	$124.11	+1.2%	+6.9%	+7.6%	+3.7%	+7.0%	+7.7%
Apr 6	Evercore ISI	Maintains	Outperform → Outperform	—	$117.78	$117.23	-0.5%	-0.7%	-2.1%	+1.7%	+1.7%	+2.0%
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$113.88	$118.60	+4.1%	+2.2%	+2.1%	+0.4%	+0.5%	-3.3%
Feb 25	Wells Fargo	Maintains	Overweight → Overweight	—	$134.67	$134.88	+0.2%	-1.9%	-0.8%	-4.4%	-7.2%	-8.6%
Feb 25	Barclays	Maintains	Overweight → Overweight	—	$134.67	$134.88	+0.2%	-1.9%	-0.8%	-4.4%	-7.2%	-8.6%
Feb 25	UBS	Maintains	Buy → Buy	—	$134.67	$134.88	+0.2%	-1.9%	-0.8%	-4.4%	-7.2%	-8.6%
Feb 25	Evercore ISI	Maintains	Outperform → Outperform	—	$134.67	$134.88	+0.2%	-1.9%	-0.8%	-4.4%	-7.2%	-8.6%
Jan 16	UBS	Maintains	Buy → Buy	—	$161.69	$162.29	+0.4%	+0.2%	+1.0%	+5.1%	+3.9%	+0.4%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$157.39	$159.86	+1.6%	+2.0%	+0.4%	-0.3%	+0.2%	+3.2%
Dec 15	Wells Fargo	Maintains	Overweight → Overweight	—	$157.39	$159.86	+1.6%	+2.0%	+0.4%	-0.3%	+0.2%	+3.2%
Oct 29	Barclays	Maintains	Overweight → Overweight	—	$151.57	$149.92	-1.1%	-2.0%	-4.6%	-1.7%	-0.9%	-3.1%
Oct 29	Canaccord Genuity	Maintains	Hold → Hold	—	$151.57	$149.92	-1.1%	-2.0%	-4.6%	-1.7%	-0.9%	-3.1%
Oct 7	Evercore ISI	Maintains	Outperform → Outperform	—	$150.10	$150.31	+0.1%	-2.8%	+0.5%	-0.9%	-3.2%	-1.0%
Oct 2	Barclays	Maintains	Overweight → Overweight	—	$145.81	$146.40	+0.4%	-0.4%	+2.0%	+2.9%	+0.1%	+3.4%
Sep 22	Evercore ISI	Upgrade	In Line → Outperform	—	$122.30	$124.93	+2.2%	+3.0%	+1.3%	+1.8%	-0.5%	+2.7%
Sep 12	Jefferies	Maintains	Hold → Hold	—	$119.51	$118.48	-0.9%	-5.0%	-4.8%	+0.2%	-0.1%	+4.1%
Sep 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$120.69	$119.96	-0.6%	-3.7%	-0.1%	+3.2%	+0.0%	-1.7%
Jul 30	Wells Fargo	Maintains	Overweight → Overweight	—	$125.30	$126.33	+0.8%	-2.0%	-6.6%	-5.1%	-7.0%	-7.5%
Jul 30	RBC Capital	Maintains	Outperform → Outperform	—	$125.30	$126.33	+0.8%	-2.0%	-6.6%	-5.1%	-7.0%	-7.5%
Jul 8	Evercore ISI	Maintains	In Line → In Line	—	$124.43	$124.73	+0.2%	+3.3%	+4.3%	+7.7%	+4.6%	-2.5%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$141.51	$140.28	-0.9%	-0.4%	-7.9%	-10.3%	-9.7%	-12.9%
Apr 30	RBC Capital	Maintains	Outperform → Outperform	—	$139.43	$139.54	+0.1%	-1.0%	-1.6%	+1.5%	+1.1%	-6.5%
Apr 29	JP Morgan	Maintains	Overweight → Overweight	—	$143.63	$135.15	-5.9%	-2.9%	-3.9%	-4.5%	-1.5%	-1.9%
Apr 16	Canaccord Genuity	Maintains	Hold → Hold	—	$126.62	$127.90	+1.0%	+4.3%	+2.7%	+4.0%	+9.7%	+11.7%
Feb 21	RBC Capital	Maintains	Outperform → Outperform	—	$162.67	$164.34	+1.0%	-2.3%	+1.3%	-0.7%	+0.1%	-3.8%
Feb 21	JP Morgan	Maintains	Overweight → Overweight	—	$162.67	$164.34	+1.0%	-2.3%	+1.3%	-0.7%	+0.1%	-3.8%
Feb 21	Canaccord Genuity	Maintains	Hold → Hold	—	$162.67	$164.34	+1.0%	-2.3%	+1.3%	-0.7%	+0.1%	-3.8%
Feb 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$162.67	$164.34	+1.0%	-2.3%	+1.3%	-0.7%	+0.1%	-3.8%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$166.84	$164.87	-1.2%	+0.6%	-0.6%	+0.7%	+4.4%	+1.5%
Jan 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$167.92	$168.53	+0.4%	-0.6%	-0.0%	-1.2%	+0.1%	+3.8%
Sep 26	RBC Capital	Maintains	Outperform → Outperform	—	$139.60	$143.21	+2.6%	+5.4%	+4.5%	+6.6%	+4.4%	+2.6%
Jul 31	RBC Capital	Maintains	Outperform → Outperform	—	$160.59	$160.97	+0.2%	+4.2%	+3.2%	+0.7%	+1.0%	+2.0%
Jul 31	JP Morgan	Maintains	Overweight → Overweight	—	$160.59	$160.97	+0.2%	+4.2%	+3.2%	+0.7%	+1.0%	+2.0%
Jul 31	UBS	Maintains	Buy → Buy	—	$160.59	$160.97	+0.2%	+4.2%	+3.2%	+0.7%	+1.0%	+2.0%
Jul 30	Stephens & Co.	Maintains	Overweight → Overweight	—	$138.00	$152.68	+10.6%	+16.4%	+21.3%	+20.1%	+17.2%	+17.5%
Jun 26	Deutsche Bank	Upgrade	Hold → Buy	—	$123.15	$126.74	+2.9%	+3.1%	+2.8%	+2.4%	+0.1%	-2.4%
May 2	JP Morgan	Maintains	Overweight → Overweight	—	$158.36	$160.61	+1.4%	+5.0%	+5.5%	+6.1%	+5.9%	+4.5%
Feb 22	Stifel	Maintains	Buy → Buy	—	$194.10	$197.28	+1.6%	-0.4%	+1.2%	-1.2%	-0.7%	+0.9%
Feb 15	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$206.04	$207.60	+0.8%	-0.0%	+1.2%	-3.1%	-5.8%	-6.1%
Dec 20	JP Morgan	Maintains	Overweight → Overweight	—	$182.10	$182.99	+0.5%	-1.3%	-0.0%	+0.3%	+0.8%	+0.9%
Dec 4	Benchmark	Downgrade	Buy → Hold	—	$164.94	$161.60	-2.0%	-2.1%	-6.3%	-5.3%	-1.9%	-3.4%
Nov 2	UBS	Maintains	Buy → Buy	—	$131.46	$137.50	+4.6%	+3.9%	+14.4%	+9.5%	+14.8%	+12.5%
Nov 1	Stifel	Maintains	Buy → Buy	—	$134.56	$132.92	-1.2%	-2.3%	+1.5%	+11.7%	+7.0%	+12.2%
Nov 1	RBC Capital	Maintains	Outperform → Outperform	—	$134.56	$132.92	-1.2%	-2.3%	+1.5%	+11.7%	+7.0%	+12.2%
Nov 1	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$134.56	$132.92	-1.2%	-2.3%	+1.5%	+11.7%	+7.0%	+12.2%
Oct 17	JP Morgan	Maintains	Overweight → Overweight	—	$153.16	$149.24	-2.6%	-4.8%	-7.0%	-4.5%	-4.7%	-6.1%
Sep 8	RBC Capital	Maintains	Outperform → Outperform	—	$168.20	$168.62	+0.2%	-4.0%	-3.1%	-6.1%	-5.5%	-1.7%
Sep 6	RBC Capital	Maintains	Outperform → Outperform	—	$169.41	$168.62	-0.5%	-1.0%	-0.7%	-4.7%	-3.7%	-6.8%
Aug 3	Stephens & Co.	Maintains	Overweight → Overweight	—	$170.48	$168.35	-1.2%	-0.9%	+1.4%	+0.5%	+1.4%	+1.4%

Recent Filings

8-K · 2.02 !! High

Repligen Corporation -- 8-K 2.02: Earnings Results

Repligen Corporation reported Q1 2026 financial results, providing investors with updated performance metrics and guidance for evaluating the bioprocess technology company's operational trajectory.

May 5

8-K

Repligen Corp -- 8-K Filing

Repligen achieved 14% organic growth in Q4 2025 driven by Analytics and Proteins segments, positioning the company favorably heading into 2026 with updated full-year guidance.

Feb 24

Data updated apr 26, 2026 10:39pm · Source: massive.com